Noha Elaidy - Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt
Eman Abdelbary - Department of Pathology, School of Medicine, Zagazig University, Zagazig, Egypt
Mohamed Hegazy - Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt
Amira Elwan - Department of Clinical Oncology and Nuclear Medicine, School of Medicine, Zagazig University, Zagazig, Egypt

Background: Programmed death- ligand ۱(PD-L۱) acts as an immune checkpoint inhibitor. Phosphatase and tensin homolog (PTEN) is a somatically mutated tumor suppressor gene in numerous types of human cancer. The current study aimed to assess the prognostic value of PD-L۱ and PTEN expression in prostatic cancer patients, as well as their relationship with the clinicopathological features of the disease.Method: A total of ۵۵ needle biopsy specimens were retrospectively diagnosed as prostatic adenocarcinoma. Immunohistochemical staining with PD-L۱ and PTEN were evaluated in all the cases. The patients were followed up for ۵ years in order to detect disease recurrence and survival.Results: PD-L۱ expression in Prostate cancer was positively correlated with high prostatic specific antigen (PSA), higher Gleason score, advanced stage, higher tumor relapse, and worse disease-free and overall survival (P < ۰.۰۰۱). PTEN loss was significantly associated with high PSA, higher Gleason score < ۷, advanced tumor stage, tumor relapse, and worse disease-free and overall survival (P < ۰.۰۰۱). We observed a significant negative correlation between PTEN and PD-L۱.Conclusion: PDL-۱ and PTEN are prognostic markers for prostate cancer, which can differentiate between the patients who are at a high risk of disease progression and may successively provide novel targeted therapies.

Prostatic Neoplasms, PD-L۱, PTEN, Immunohistochemistry, Prognosis